<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0122-0667</journal-id>
<journal-title><![CDATA[Revista Médica de Risaralda]]></journal-title>
<abbrev-journal-title><![CDATA[Revista médica Risaralda]]></abbrev-journal-title>
<issn>0122-0667</issn>
<publisher>
<publisher-name><![CDATA[Universidad Tecnológica de Pereira]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0122-06672019000200129</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Patrones de prescripción de heparinas en 14 centros hospitalarios de Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Prescribing patterns of heparins in 14 hospitals of Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[Manuel E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Leidy Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quintero-Chica]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira Facultad de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria Autónoma de las Américas  ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>25</volume>
<numero>2</numero>
<fpage>129</fpage>
<lpage>137</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0122-06672019000200129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0122-06672019000200129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0122-06672019000200129&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  las heparinas son esenciales para el manejo de muchos pacientes en los servicios de hospitalización. Objetivo: determinar los patrones de prescripción de heparinas en distintos ambientes hospitalarios en Colombia.  Metodología: estudio observacional con prescripciones de pacientes tratados con heparinas en 14 clínicas de 12 ciudades colombianas durante octubre de 2015. Se evaluaron variables sociodemográficas, farmacológicas, comedicaciones; se realizaron análisis descriptivos y multivariados.  Resultados: se encontraron 3 776 pacientes tratados con heparinas, con edad promedio: 60,1 ± 20,1 años, 56,9 % fueron mujeres; con una prevalencia de uso de 9,1 %, se emplearon en promedio 6,3 dosis por sujeto, siendo enoxaparina (74,8 %), y dalteparina (24,9 %) los más utilizados. Se prescribió terapia combinada con dos antiagregantes en 34,1 % de casos y las comedicaciones más frecuentes fueron antiinflamatorios no esteroideos (28,9 %) y benzodiazepinas (14,6 %). El uso de dalteparina, haber sido atendido en Cartagena, Barranquilla y ser adulto joven se asociaron con menor probabilidad de recibir alguna comedicación.  Conclusión:  predomina el uso de heparinas de bajo peso molecular sin utilización de la heparina convencional en las clínicas evaluadas, lo que puede estar asociado con su fácil manejo, menores efectos secundarios y mayor costo-efectividad haciéndolas más convenientes para el uso intrahospitalario.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Heparins are essential for the management of many patients in inpatient services.  Objective.  To determine the prescribing patterns of heparins in hospitals in a group of patients of Colombia.  Methods.  An observational study with data of prescriptions of patients treated with heparins in 14 hospitals in 12 cities of Colombia during October 2015. Sociodemographic, pharmacological, combined therapy, and co-medication variables were evaluated. Descriptive and multivariate analyzes were performed.  Results.  A total of 3776 patients on heparin treatment were found; mean age: 60.1±20.1 years, 56.9 % were women; with a prevalence of 9.1 %; a mean of 6.3 doses per patient was used. Enoxaparin (74.8 %) and dalteparin (24.9 %) being the most used injecting anticoagulants. Dual antiplatelet therapy was prescribed in 34.1 % of cases, and the most frequent co-medications were non-steroidal anti-inflammatory drugs (28.9 %), benzodiazepines (14.6 %). The use of dalteparin, have been treated in Cartagena, Barranquilla and being a young adult, reduced the risk of receiving some co-medication.  Conclusion.  The use of low-molecular-weight-heparins is predominant without the use of conventional heparins in clinics, which may be associated with their easy use, less side effects and greater cost-effectiveness, making them more convenient for intra-hospital use.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anticoagulantes]]></kwd>
<kwd lng="es"><![CDATA[Heparina]]></kwd>
<kwd lng="es"><![CDATA[Farmacoepidemiología]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[Heparin]]></kwd>
<kwd lng="en"><![CDATA[Pharmacoepidemiology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation Drug Therapy: A Review]]></article-title>
<source><![CDATA[West J Emerg Med]]></source>
<year>2015</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveros]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lobelo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis costo-efectividad de las heparinas de bajo peso molecular en tromboprofilaxis temprana en pacientes médicos y quirúrgicos]]></article-title>
<source><![CDATA[Acta Médica Colombiana]]></source>
<year>2006</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>71-82</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panday]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Humphrey]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication-induced osteoporosis: screening and treatment strategies]]></article-title>
<source><![CDATA[Ther Adv Musculoskelet Dis]]></source>
<year>2014</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>185-202</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelton]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonheparin anticoagulants for heparin-induced thrombocytopenia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>737-44</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Raskob]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Landefeld]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kearon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemorrhagic complications of anticoagulant treatment]]></article-title>
<source><![CDATA[Chest Journal]]></source>
<year>2001</year>
<volume>119</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>108S-21S</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shorr]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Sherner]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Moores]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis]]></article-title>
<source><![CDATA[Chest Journal]]></source>
<year>2008</year>
<volume>133</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>149-55</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haighton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kempen]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Wolterbeek]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Marting]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
<name>
<surname><![CDATA[van Dijk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Veen]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bridging therapy for oral anticoagulation increases the risk for bleeding-related complications in total joint arthroplasty]]></article-title>
<source><![CDATA[J Orthop Surg Res]]></source>
<year>2015</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo Presti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aular]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacciones farmacológicas potenciales en pacientes con enfermedad cardiovascular polimedicados]]></article-title>
<source><![CDATA[Salus]]></source>
<year>2015</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>11-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[iryaki]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nutescu]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Hennenfent]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Karageanes]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Koesterer]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Schumock]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures]]></article-title>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2011</year>
<volume>68</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1239-44</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shimazui]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2010</year>
<volume>125</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e65-70</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardona-Ospina]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Cano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cano]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Cerón]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Valencia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thromboprophylaxis in hospitalized patients, are we doing the right thing]]></article-title>
<source><![CDATA[Rev Méd Risaralda]]></source>
<year>2013</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Phatak]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Qi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Teal]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nisi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological Prophylaxis for Venous Thromboembolism Among Hospitalized Patients With Acute Medical Illness: An Electronic Medical Records Study]]></article-title>
<source><![CDATA[Am J Ther]]></source>
<year>2016</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e328-35</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chandrasekhar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mehran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>2015</year>
<volume>58</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>247-59</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Blas Matas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Velasco]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Castrillón]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacciones de los fármacos más consumidos]]></article-title>
<source><![CDATA[Información terapéutica del Sistema Nacional de Salud]]></source>
<year>2004</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mino-León]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Galván-Plata]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Doubova]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Hernandez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Morales]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio farmacoepidemiológico de potenciales interacciones farmacológicas y sus determinantes, en pacientes hospitalizados]]></article-title>
<source><![CDATA[Rev Inv Clin]]></source>
<year>2011</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>170-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lacy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Goldman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lance]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Information Handbook]]></source>
<year>2016</year>
<page-range>2035</page-range><publisher-loc><![CDATA[Ohio, United States ]]></publisher-loc>
<publisher-name><![CDATA[Lexicomp Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roach]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sadler]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Belshaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkness]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Who gets stroke prevention? Stroke prevention in atrial fibrillation patients in the inpatient setting]]></article-title>
<source><![CDATA[Heart Lung Circ]]></source>
<year>2015</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>488-94</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Valencia-Marulanda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Canizales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patrones de prescripción de hormonas tiroideas en una población colombiana]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2014</year>
<volume>36</volume>
<page-range>80-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Plaza]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patrones de prescripción de antidepresivos en pacientes afiliados al Sistema General de Seguridad Social en Salud de Colombia]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2011</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>461</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
